Scientists have identified a new genetic link to chronic pain and discovered a promising drug target to alleviate the debilitating condition. A team led by Professor David Bennett, working with Professor Simon Newstead, has found that a gene called SLC45A4 is linked to pain signaling in the body.
The researchers used UK Biobank and other population studies to compare genetic data with participant responses to a questionnaire on pain. They discovered that people with a variant of SLC45A4 were more likely to report higher levels of pain, which was replicated in other major studies.
Further investigation revealed that SLC45A4 encodes a neuronal polyamine transporter, crucial for regulating how nerves respond to painful stimuli. The team determined the structure of this transporter using cryo-electron microscopy and confirmed its role in sending polyamines across nerve cells.
The findings have significant implications for treating chronic pain without relying on strong opioids, which can lead to addiction and long-term health impacts. If a successful drug is developed based on this new target, it could revolutionize the treatment of chronic pain worldwide.
Professor Bennett said that his team’s discovery reveals a promising new target for alleviating chronic pain. With further research, their findings may pave the way for safer and more effective treatments for patients.
Source: https://medicalxpress.com/news/2025-08-genetic-link-pain-drug.html